

Global Neuraminidase Inhibitors Drug Market Research Report 2023

<https://marketpublishers.com/r/G46F7FCEB5B6EN.html>

Date: December 2023

Pages: 80

Price: US\$ 2,900.00 (Single User License)

ID: G46F7FCEB5B6EN

Abstracts

Neuraminidase Inhibitors (NAIs) are the type of drugs that are used to block the neuraminidase enzyme.

According to QYResearch's new survey, global Neuraminidase Inhibitors Drug market is projected to reach US\$ 1386.5 million in 2029, increasing from US\$ 928 million in 2022, with the CAGR of 5.9% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Neuraminidase Inhibitors Drug market research.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Neuraminidase Inhibitors Drug market with multiple angles, which provides sufficient supports to readers' strategy and decision making.

By Company

Roche

GSK

Gilead Sciences

Daiichi Sankyo

AstraZeneca

Pfizer

Teva

Bristol-Myers Squibb

Sun Pharmaceutical

Segment by Type

Oseltamivir

Zanamivir

Peramivir

Laninamivir

Segment by Application

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Others

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

The Neuraminidase Inhibitors Drug report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)

Chapter 2: Global market size, regional market size. Market Opportunities and Challenges

Chapter 3: Companies' Competition Patterns

Chapter 4: Product Type Analysis

Chapter 5: Product Application Analysis

Chapter 6 to 10: Country Level Value Analysis

Chapter 11: Companies' Outline

Chapter 12: Market Conclusions

Chapter 13: Research Methodology and Data Source

Contents

1 REPORT OVERVIEW

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Oseltamivir

1.2.3 Zanamivir

1.2.4 Peramivir

1.2.5 Laninamivir

1.3 Market by Application

1.3.1 Global Neuraminidase Inhibitors Drug Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospital Pharmacy

1.3.3 Retail Pharmacy

1.3.4 Online Pharmacy

1.3.5 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 GLOBAL GROWTH TRENDS

2.1 Global Neuraminidase Inhibitors Drug Market Perspective (2018-2029)

2.2 Neuraminidase Inhibitors Drug Growth Trends by Region

2.2.1 Global Neuraminidase Inhibitors Drug Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Neuraminidase Inhibitors Drug Historic Market Size by Region (2018-2023)

2.2.3 Neuraminidase Inhibitors Drug Forecasted Market Size by Region (2024-2029)

2.3 Neuraminidase Inhibitors Drug Market Dynamics

2.3.1 Neuraminidase Inhibitors Drug Industry Trends

2.3.2 Neuraminidase Inhibitors Drug Market Drivers

2.3.3 Neuraminidase Inhibitors Drug Market Challenges

2.3.4 Neuraminidase Inhibitors Drug Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Neuraminidase Inhibitors Drug Players by Revenue

3.1.1 Global Top Neuraminidase Inhibitors Drug Players by Revenue (2018-2023)

3.1.2 Global Neuraminidase Inhibitors Drug Revenue Market Share by Players (2018-2023)

3.2 Global Neuraminidase Inhibitors Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Neuraminidase Inhibitors Drug Revenue

3.4 Global Neuraminidase Inhibitors Drug Market Concentration Ratio

3.4.1 Global Neuraminidase Inhibitors Drug Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Neuraminidase Inhibitors Drug Revenue in 2022

3.5 Neuraminidase Inhibitors Drug Key Players Head office and Area Served

3.6 Key Players Neuraminidase Inhibitors Drug Product Solution and Service

3.7 Date of Enter into Neuraminidase Inhibitors Drug Market

3.8 Mergers & Acquisitions, Expansion Plans

4 NEURAMINIDASE INHIBITORS DRUG BREAKDOWN DATA BY TYPE

4.1 Global Neuraminidase Inhibitors Drug Historic Market Size by Type (2018-2023)

4.2 Global Neuraminidase Inhibitors Drug Forecasted Market Size by Type (2024-2029)

5 NEURAMINIDASE INHIBITORS DRUG BREAKDOWN DATA BY APPLICATION

5.1 Global Neuraminidase Inhibitors Drug Historic Market Size by Application (2018-2023)

5.2 Global Neuraminidase Inhibitors Drug Forecasted Market Size by Application (2024-2029)

6 NORTH AMERICA

6.1 North America Neuraminidase Inhibitors Drug Market Size (2018-2029)

6.2 North America Neuraminidase Inhibitors Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Neuraminidase Inhibitors Drug Market Size by Country (2018-2023)

6.4 North America Neuraminidase Inhibitors Drug Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7 EUROPE

- 7.1 Europe Neuraminidase Inhibitors Drug Market Size (2018-2029)
- 7.2 Europe Neuraminidase Inhibitors Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 7.3 Europe Neuraminidase Inhibitors Drug Market Size by Country (2018-2023)
- 7.4 Europe Neuraminidase Inhibitors Drug Market Size by Country (2024-2029)
- 7.5 Germany
- 7.6 France
- 7.7 U.K.
- 7.8 Italy
- 7.9 Russia
- 7.10 Nordic Countries

8 ASIA-PACIFIC

- 8.1 Asia-Pacific Neuraminidase Inhibitors Drug Market Size (2018-2029)
- 8.2 Asia-Pacific Neuraminidase Inhibitors Drug Market Growth Rate by Region: 2018 VS 2022 VS 2029
- 8.3 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region (2018-2023)
- 8.4 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region (2024-2029)
- 8.5 China
- 8.6 Japan
- 8.7 South Korea
- 8.8 Southeast Asia
- 8.9 India
- 8.10 Australia

9 LATIN AMERICA

- 9.1 Latin America Neuraminidase Inhibitors Drug Market Size (2018-2029)
- 9.2 Latin America Neuraminidase Inhibitors Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 9.3 Latin America Neuraminidase Inhibitors Drug Market Size by Country (2018-2023)
- 9.4 Latin America Neuraminidase Inhibitors Drug Market Size by Country (2024-2029)
- 9.5 Mexico
- 9.6 Brazil

10 MIDDLE EAST & AFRICA

- 10.1 Middle East & Africa Neuraminidase Inhibitors Drug Market Size (2018-2029)
- 10.2 Middle East & Africa Neuraminidase Inhibitors Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 10.3 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2018-2023)
- 10.4 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2024-2029)
- 10.5 Turkey
- 10.6 Saudi Arabia
- 10.7 UAE

11 KEY PLAYERS PROFILES

11.1 Roche

- 11.1.1 Roche Company Detail
- 11.1.2 Roche Business Overview
- 11.1.3 Roche Neuraminidase Inhibitors Drug Introduction
- 11.1.4 Roche Revenue in Neuraminidase Inhibitors Drug Business (2018-2023)
- 11.1.5 Roche Recent Development

11.2 GSK

- 11.2.1 GSK Company Detail
- 11.2.2 GSK Business Overview
- 11.2.3 GSK Neuraminidase Inhibitors Drug Introduction
- 11.2.4 GSK Revenue in Neuraminidase Inhibitors Drug Business (2018-2023)
- 11.2.5 GSK Recent Development

11.3 Gilead Sciences

- 11.3.1 Gilead Sciences Company Detail
- 11.3.2 Gilead Sciences Business Overview
- 11.3.3 Gilead Sciences Neuraminidase Inhibitors Drug Introduction
- 11.3.4 Gilead Sciences Revenue in Neuraminidase Inhibitors Drug Business (2018-2023)
- 11.3.5 Gilead Sciences Recent Development

11.4 Daiichi Sankyo

- 11.4.1 Daiichi Sankyo Company Detail
- 11.4.2 Daiichi Sankyo Business Overview
- 11.4.3 Daiichi Sankyo Neuraminidase Inhibitors Drug Introduction
- 11.4.4 Daiichi Sankyo Revenue in Neuraminidase Inhibitors Drug Business (2018-2023)

- 11.4.5 Daiichi Sankyo Recent Development
- 11.5 AstraZeneca
 - 11.5.1 AstraZeneca Company Detail
 - 11.5.2 AstraZeneca Business Overview
 - 11.5.3 AstraZeneca Neuraminidase Inhibitors Drug Introduction
 - 11.5.4 AstraZeneca Revenue in Neuraminidase Inhibitors Drug Business (2018-2023)
 - 11.5.5 AstraZeneca Recent Development
- 11.6 Pfizer
 - 11.6.1 Pfizer Company Detail
 - 11.6.2 Pfizer Business Overview
 - 11.6.3 Pfizer Neuraminidase Inhibitors Drug Introduction
 - 11.6.4 Pfizer Revenue in Neuraminidase Inhibitors Drug Business (2018-2023)
 - 11.6.5 Pfizer Recent Development
- 11.7 Teva
 - 11.7.1 Teva Company Detail
 - 11.7.2 Teva Business Overview
 - 11.7.3 Teva Neuraminidase Inhibitors Drug Introduction
 - 11.7.4 Teva Revenue in Neuraminidase Inhibitors Drug Business (2018-2023)
 - 11.7.5 Teva Recent Development
- 11.8 Bristol-Myers Squibb
 - 11.8.1 Bristol-Myers Squibb Company Detail
 - 11.8.2 Bristol-Myers Squibb Business Overview
 - 11.8.3 Bristol-Myers Squibb Neuraminidase Inhibitors Drug Introduction
 - 11.8.4 Bristol-Myers Squibb Revenue in Neuraminidase Inhibitors Drug Business (2018-2023)
 - 11.8.5 Bristol-Myers Squibb Recent Development
- 11.9 Sun Pharmaceutical
 - 11.9.1 Sun Pharmaceutical Company Detail
 - 11.9.2 Sun Pharmaceutical Business Overview
 - 11.9.3 Sun Pharmaceutical Neuraminidase Inhibitors Drug Introduction
 - 11.9.4 Sun Pharmaceutical Revenue in Neuraminidase Inhibitors Drug Business (2018-2023)
 - 11.9.5 Sun Pharmaceutical Recent Development

12 ANALYST'S VIEWPOINTS/CONCLUSIONS

13 APPENDIX

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Type (US\$ Million): 2018 VS 2022 VS 2029

Table 2. Key Players of Oseltamivir

Table 3. Key Players of Zanamivir

Table 4. Key Players of Peramivir

Table 5. Key Players of Laninamivir

Table 6. Global Neuraminidase Inhibitors Drug Market Size Growth by Application (US\$ Million): 2018 VS 2022 VS 2029

Table 7. Global Neuraminidase Inhibitors Drug Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 8. Global Neuraminidase Inhibitors Drug Market Size by Region (2018-2023) & (US\$ Million)

Table 9. Global Neuraminidase Inhibitors Drug Market Share by Region (2018-2023)

Table 10. Global Neuraminidase Inhibitors Drug Forecasted Market Size by Region (2024-2029) & (US\$ Million)

Table 11. Global Neuraminidase Inhibitors Drug Market Share by Region (2024-2029)

Table 12. Neuraminidase Inhibitors Drug Market Trends

Table 13. Neuraminidase Inhibitors Drug Market Drivers

Table 14. Neuraminidase Inhibitors Drug Market Challenges

Table 15. Neuraminidase Inhibitors Drug Market Restraints

Table 16. Global Neuraminidase Inhibitors Drug Revenue by Players (2018-2023) & (US\$ Million)

Table 17. Global Neuraminidase Inhibitors Drug Market Share by Players (2018-2023)

Table 18. Global Top Neuraminidase Inhibitors Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuraminidase Inhibitors Drug as of 2022)

Table 19. Ranking of Global Top Neuraminidase Inhibitors Drug Companies by Revenue (US\$ Million) in 2022

Table 20. Global 5 Largest Players Market Share by Neuraminidase Inhibitors Drug Revenue (CR5 and HHI) & (2018-2023)

Table 21. Key Players Headquarters and Area Served

Table 22. Key Players Neuraminidase Inhibitors Drug Product Solution and Service

Table 23. Date of Enter into Neuraminidase Inhibitors Drug Market

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Neuraminidase Inhibitors Drug Market Size by Type (2018-2023) &

(US\$ Million)

Table 26. Global Neuraminidase Inhibitors Drug Revenue Market Share by Type (2018-2023)

Table 27. Global Neuraminidase Inhibitors Drug Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 28. Global Neuraminidase Inhibitors Drug Revenue Market Share by Type (2024-2029)

Table 29. Global Neuraminidase Inhibitors Drug Market Size by Application (2018-2023) & (US\$ Million)

Table 30. Global Neuraminidase Inhibitors Drug Revenue Market Share by Application (2018-2023)

Table 31. Global Neuraminidase Inhibitors Drug Forecasted Market Size by Application (2024-2029) & (US\$ Million)

Table 32. Global Neuraminidase Inhibitors Drug Revenue Market Share by Application (2024-2029)

Table 33. North America Neuraminidase Inhibitors Drug Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 34. North America Neuraminidase Inhibitors Drug Market Size by Country (2018-2023) & (US\$ Million)

Table 35. North America Neuraminidase Inhibitors Drug Market Size by Country (2024-2029) & (US\$ Million)

Table 36. Europe Neuraminidase Inhibitors Drug Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 37. Europe Neuraminidase Inhibitors Drug Market Size by Country (2018-2023) & (US\$ Million)

Table 38. Europe Neuraminidase Inhibitors Drug Market Size by Country (2024-2029) & (US\$ Million)

Table 39. Asia-Pacific Neuraminidase Inhibitors Drug Market Size Growth Rate by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 40. Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region (2018-2023) & (US\$ Million)

Table 41. Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region (2024-2029) & (US\$ Million)

Table 42. Latin America Neuraminidase Inhibitors Drug Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 43. Latin America Neuraminidase Inhibitors Drug Market Size by Country (2018-2023) & (US\$ Million)

Table 44. Latin America Neuraminidase Inhibitors Drug Market Size by Country (2024-2029) & (US\$ Million)

Table 45. Middle East & Africa Neuraminidase Inhibitors Drug Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 46. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2018-2023) & (US\$ Million)

Table 47. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2024-2029) & (US\$ Million)

Table 48. Roche Company Detail

Table 49. Roche Business Overview

Table 50. Roche Neuraminidase Inhibitors Drug Product

Table 51. Roche Revenue in Neuraminidase Inhibitors Drug Business (2018-2023) & (US\$ Million)

Table 52. Roche Recent Development

Table 53. GSK Company Detail

Table 54. GSK Business Overview

Table 55. GSK Neuraminidase Inhibitors Drug Product

Table 56. GSK Revenue in Neuraminidase Inhibitors Drug Business (2018-2023) & (US\$ Million)

Table 57. GSK Recent Development

Table 58. Gilead Sciences Company Detail

Table 59. Gilead Sciences Business Overview

Table 60. Gilead Sciences Neuraminidase Inhibitors Drug Product

Table 61. Gilead Sciences Revenue in Neuraminidase Inhibitors Drug Business (2018-2023) & (US\$ Million)

Table 62. Gilead Sciences Recent Development

Table 63. Daiichi Sankyo Company Detail

Table 64. Daiichi Sankyo Business Overview

Table 65. Daiichi Sankyo Neuraminidase Inhibitors Drug Product

Table 66. Daiichi Sankyo Revenue in Neuraminidase Inhibitors Drug Business (2018-2023) & (US\$ Million)

Table 67. Daiichi Sankyo Recent Development

Table 68. AstraZeneca Company Detail

Table 69. AstraZeneca Business Overview

Table 70. AstraZeneca Neuraminidase Inhibitors Drug Product

Table 71. AstraZeneca Revenue in Neuraminidase Inhibitors Drug Business (2018-2023) & (US\$ Million)

Table 72. AstraZeneca Recent Development

Table 73. Pfizer Company Detail

Table 74. Pfizer Business Overview

Table 75. Pfizer Neuraminidase Inhibitors Drug Product

Table 76. Pfizer Revenue in Neuraminidase Inhibitors Drug Business (2018-2023) & (US\$ Million)

Table 77. Pfizer Recent Development

Table 78. Teva Company Detail

Table 79. Teva Business Overview

Table 80. Teva Neuraminidase Inhibitors Drug Product

Table 81. Teva Revenue in Neuraminidase Inhibitors Drug Business (2018-2023) & (US\$ Million)

Table 82. Teva Recent Development

Table 83. Bristol-Myers Squibb Company Detail

Table 84. Bristol-Myers Squibb Business Overview

Table 85. Bristol-Myers Squibb Neuraminidase Inhibitors Drug Product

Table 86. Bristol-Myers Squibb Revenue in Neuraminidase Inhibitors Drug Business (2018-2023) & (US\$ Million)

Table 87. Bristol-Myers Squibb Recent Development

Table 88. Sun Pharmaceutical Company Detail

Table 89. Sun Pharmaceutical Business Overview

Table 90. Sun Pharmaceutical Neuraminidase Inhibitors Drug Product

Table 91. Sun Pharmaceutical Revenue in Neuraminidase Inhibitors Drug Business (2018-2023) & (US\$ Million)

Table 92. Sun Pharmaceutical Recent Development

Table 93. Research Programs/Design for This Report

Table 94. Key Data Information from Secondary Sources

Table 95. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

- Figure 1. Global Neuraminidase Inhibitors Drug Market Size Comparison by Type (2023-2029) & (US\$ Million)
- Figure 2. Global Neuraminidase Inhibitors Drug Market Share by Type: 2022 VS 2029
- Figure 3. Oseltamivir Features
- Figure 4. Zanamivir Features
- Figure 5. Peramivir Features
- Figure 6. Laninamivir Features
- Figure 7. Global Neuraminidase Inhibitors Drug Market Size Comparison by Application (2023-2029) & (US\$ Million)
- Figure 8. Global Neuraminidase Inhibitors Drug Market Share by Application: 2022 VS 2029
- Figure 9. Hospital Pharmacy Case Studies
- Figure 10. Retail Pharmacy Case Studies
- Figure 11. Online Pharmacy Case Studies
- Figure 12. Others Case Studies
- Figure 13. Neuraminidase Inhibitors Drug Report Years Considered
- Figure 14. Global Neuraminidase Inhibitors Drug Market Size (US\$ Million), Year-over-Year: 2018-2029
- Figure 15. Global Neuraminidase Inhibitors Drug Market Size, (US\$ Million), 2018 VS 2022 VS 2029
- Figure 16. Global Neuraminidase Inhibitors Drug Market Share by Region: 2022 VS 2029
- Figure 17. Global Neuraminidase Inhibitors Drug Market Share by Players in 2022
- Figure 18. Global Top Neuraminidase Inhibitors Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuraminidase Inhibitors Drug as of 2022)
- Figure 19. The Top 10 and 5 Players Market Share by Neuraminidase Inhibitors Drug Revenue in 2022
- Figure 20. North America Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 21. North America Neuraminidase Inhibitors Drug Market Share by Country (2018-2029)
- Figure 22. United States Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 23. Canada Neuraminidase Inhibitors Drug Market Size YoY Growth

(2018-2029) & (US\$ Million)

Figure 24. Europe Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 25. Europe Neuraminidase Inhibitors Drug Market Share by Country (2018-2029)

Figure 26. Germany Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 27. France Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 28. U.K. Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 29. Italy Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 30. Russia Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 31. Nordic Countries Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 32. Asia-Pacific Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 33. Asia-Pacific Neuraminidase Inhibitors Drug Market Share by Region (2018-2029)

Figure 34. China Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 35. Japan Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 36. South Korea Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 37. Southeast Asia Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 38. India Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 39. Australia Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 40. Latin America Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 41. Latin America Neuraminidase Inhibitors Drug Market Share by Country (2018-2029)

Figure 42. Mexico Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 43. Brazil Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) &

(US\$ Million)

Figure 44. Middle East & Africa Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 45. Middle East & Africa Neuraminidase Inhibitors Drug Market Share by Country (2018-2029)

Figure 46. Turkey Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 47. Saudi Arabia Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 48. Roche Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2023)

Figure 49. GSK Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2023)

Figure 50. Gilead Sciences Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2023)

Figure 51. Daiichi Sankyo Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2023)

Figure 52. AstraZeneca Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2023)

Figure 53. Pfizer Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2023)

Figure 54. Teva Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2023)

Figure 55. Bristol-Myers Squibb Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2023)

Figure 56. Sun Pharmaceutical Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2023)

Figure 57. Bottom-up and Top-down Approaches for This Report

Figure 58. Data Triangulation

Figure 59. Key Executives Interviewed

I would like to order

Product name: Global Neuraminidase Inhibitors Drug Market Research Report 2023

Product link: <https://marketpublishers.com/r/G46F7FCEB5B6EN.html>

Price: US\$ 2,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G46F7FCEB5B6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970